

|                                                                   |                                                                                                                                                                                                                                                                                   |                                |                 |
|-------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|-----------------|
| <b>ASRS 2026 Annual Meeting</b>                                   |                                                                                                                                                                                                                                                                                   | <b>Last edit: May 18, 2026</b> |                 |
| <b>Wednesday, July 15</b>                                         |                                                                                                                                                                                                                                                                                   |                                |                 |
| <b>Continental Breakfast</b>                                      |                                                                                                                                                                                                                                                                                   | <b>7:15 AM</b>                 | <b>8:15 AM</b>  |
| <b>Retina Around the Globe (No CME, livestream, or recording)</b> | <b>Team 1</b> <u>Moderators</u> : RV Paul Chan, MD, MSc, MBA and Mrinali Gupta, MD, FASRS <u>Presenters</u> : Gustavo Huning, MD, MBA, FASRS; Ajay Kuriyan, MD, MS; Ahmed Mansour, MBBCH, MSc, MD, PhD; Ayumi Ouchi, MD, MD, PhD; Cynthia Qian, MD                                | <b>8:00 AM</b>                 | <b>11:00 AM</b> |
|                                                                   | <b>Team 2</b> <u>Moderators</u> : Rajeev Muni, MD, MSc, FRCS(C), FASRS and Nimesh Patel, MD, FASRS <u>Presenters</u> : Lalit Agarwal, MD; Kunihiko Akiyama, MD, PhD; Thibault Chapron, MD, PhD; Luis Escaf, MD; Natasha Ferreira Santos da Cruz, MD; Jessica Xiong, BMed/MD, Mmed |                                |                 |
|                                                                   | <b>Team 3</b> <u>Moderators</u> : Jorge Fortun, MD and Aleksandra Rachitskaya, MD, FASRS <u>Presenters</u> : Fares Antaki, MDCM, FRCSC; Andres Aqueveque, MD, FEBO, PhD; Bruna Gil Ferriera, MD; Yassine Malek, MD; Joaquin Sosa, MD; Marcelo Ventura, MD                         |                                |                 |
| <b>Circus of Complications (No CME, livestream, or recording)</b> | <u>Moderators</u> : Brian Do, MD, FASRS; Priya Vakharia, MD, FASRS                                                                                                                                                                                                                | <b>11:00 AM</b>                | <b>12:15 PM</b> |
|                                                                   | <u>Presenters</u> : Masaki Fukushima, MD; Edward Korot, MD; Gregory Lee, MD; Tamara Lenis, MD, PhD; Matthew Trese, DO, MA; Malek Yassine, MD; Sarwar Zahid, MD, FASRS                                                                                                             |                                |                 |
| <b>General Lunch + International Lunch; Exhibits Open</b>         |                                                                                                                                                                                                                                                                                   | <b>12:15 PM</b>                | <b>1:30 PM</b>  |
| <b>Medical Case Conference</b>                                    | <u>Moderators</u> : Ines Lains, MD, PhD; Anat Loewenstein, MD                                                                                                                                                                                                                     | <b>1:30 PM</b>                 | <b>3:00 PM</b>  |

|                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                |                |
|--------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|----------------|
|                                                                                                        | <p><u>Presenters:</u> Mohamed Al Bahiti, MBBS, FRCSC; Parnian Arjmand, MD, MSc, FRCSC, DABO; Poornachandra B, MS, FVRS; Kevin Blinder, MD, FASRS; Victor Chen, MD; Talisa de Carlo Forest, MD; Hector Ibanez, MD, FACS, FASRS, FABO, FFAO; Matias Igllicki, MD; Ravi Keshavamurthy, MBBS, MD; Ricardo Leal Rodriguez, MD; Sun Young (Sunny) Lee, MD, PhD, FASRS, FARVO; Yasha Modi, MD; Nader Moinfar, MD, MPH, FACS, FASRS; Samir Patel, MD; Sriharanathan Poopalaratnam, MD, FRCSC; Emil Anthony Say, MD; Kotaro Tsuboi, MD; Eduardo Uchiyama, MD, FACS</p> |                |                |
| Break                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | <b>3:00 PM</b> | <b>3:40 PM</b> |
| <b>Surgical Case Conference</b>                                                                        | <p><u>Moderators:</u> Carl Awh, MD, FASRS; Caroline Awh, MD</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | <b>3:40 PM</b> | <b>5:10 PM</b> |
|                                                                                                        | <p><u>Presenters:</u> Luis Acaba-Berrocal, MD; Sulaiman Al Sulaiman, MD; Alay Banker, MD; Mauricio Bayram-Suverza, MD; Yodpong Chantarasorn, MD; Jordan Deaner, MD; Charles DeBoer, MD, PhD; Masaki Fukushima, MD, PhD; Raymond Iezzi, MD, MS; Srinivas Joshi, MD, FASRS; Boonkit Purt, MD, FACS; Padmaja Rani, M.S, FICO, FRCSC; Mary-Grace Reeves, MD, MBA; Geovanni Rios, PhD, MD; Pukhraj Rishi, MBBS, MS, DO, FRCS, FRCSEd, FASRS, FACS; Ahmed Sallam, MD PhD FRCOphth; Homayoun Tabandeh, MD, FASRS; Christina Weng, MD, MBA, FASRS</p>                 |                |                |
| Opening Reception: Grand Quai Pavilion                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | <b>6:30 PM</b> |                |
| <b>Thursday, July 16</b>                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                |                |
| <b>Experience Center (Fellows &amp; Residents)</b>                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | <b>6:30 AM</b> | <b>7:30 AM</b> |
| <b>Continental Breakfast</b>                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | <b>7:15 AM</b> | <b>8:15 AM</b> |
| <b>Opening Comments</b>                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | <b>8:00 AM</b> | <b>8:05 AM</b> |
| <b>Welcome to Montreal</b>                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | <b>8:05 AM</b> | <b>8:10 AM</b> |
| <b>AMD - Neovascular Panel. <i>Beyond Anti-VEGF: Emerging Durable Therapies in Neovascular AMD</i></b> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | <b>8:10 AM</b> | <b>8:45 AM</b> |

|                                                                                                                                                        |                                         |                |                |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|----------------|----------------|
| One-year, First-in-Human, Safety and Efficacy Data for Subretinal NG101 - a Novel Low-dose AAV Gene Therapy for Wet AMD: A Phase 1/2a Clinical Trial   | <b>Peter Kertes, MD, FRCS(C)</b>        |                |                |
| Ixoberogene soroparvovec (Ixo-vec) intravitreal gene therapy for neovascular age-related macular degeneration (nAMD): LUNA trial 2-year results        | <b>Shawn Kavoussi, MD</b>               |                |                |
| Ixoberogene soroparvovec intravitreal gene therapy for neovascular age-related macular degeneration: Long-term results from the OPTIC trial            | <b>Szilard Kiss, MD, FASRS</b>          |                |                |
| Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular Age-Related Macular Degeneration: Efficacy and Safety Results from the Phase 3 SOL-1 Trial     | <b>Dilsher Dhoot, MD</b>                |                |                |
| Results of a Randomized, Proof-of-Concept Clinical Trial Comparing OLN324 with Faricimab in Patients with Neovascular Age-Related Macular Degeneration | <b>David Eichenbaum, MD, FASRS</b>      |                |                |
| Efficacy and safety of aflibercept 8 mg in previously treated patients with nAMD or DME: 24-week results from the phase 3b ELARA trial                 | <b>Eric Schneider, MD</b>               |                |                |
| Discussion                                                                                                                                             |                                         |                |                |
| <i>Transition</i>                                                                                                                                      |                                         | 8:45 AM        | 8:47 AM        |
| <b>Real-World Symposium 1. Real-World nAMD: Utilization, Outcomes, and Long-Term Anti-VEGF Data</b>                                                    |                                         | <b>8:47 AM</b> | <b>9:11 AM</b> |
| Utilization and Trends in Anti-Angiogenic and Anti-Complement Therapeutics from 2023-2025                                                              | <b>Anton Kolomeyer, MD, PhD</b>         | 8:47 AM        | 8:50 AM        |
| Real-World Anti-VEGF Treatment Utilization and Vision Outcomes in Neovascular Age-Related Macular Degeneration: Analysis of the Vestrum Database       | <b>Andrew Moshfeghi, MD, MBA, FASRS</b> | 8:50 AM        | 8:53 AM        |
| Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: First Time 4.5 Year Results of the TRUCKEE Study          | <b>Carl Danzig, MD</b>                  | 8:53 AM        | 8:56 AM        |
| Long-Term Effectiveness and Safety of Faricimab in Eyes With nAMD: 2-Year Results From the UK FARWIDE Study                                            | <b>Ian Pearce, MB ChB BSc FRCOPHTH</b>  | 8:56 AM        | 8:59 AM        |
| Discussion                                                                                                                                             |                                         | 8:59 AM        | 9:11 AM        |
| <i>Transition</i>                                                                                                                                      |                                         | 9:11 AM        | 9:13 AM        |

|                                                                                                                                                                      |                                          |                 |                 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|-----------------|-----------------|
| <b>Surgical Techniques and Maneuvers Panel. <i>Mastering Scleral Fixation: Techniques, Pearls, and Pitfalls</i></b>                                                  |                                          | <b>9:13 AM</b>  | <b>9:43 AM</b>  |
| A NOVEL MODIFIED FLAPLESS SURGICAL TECHNIQUE FOR SUTURELESS SCLERAL FIXATION OF FIL SSF INTRAOCULAR LENS: A PROSPECTIVE STUDY                                        | <b>Danilo Iannetta, MD, PhD</b>          |                 |                 |
| Closed-Globe Internal Refixation of Dislocated PMMA Scleral-Fixated IOLs Using a Modified Double-Flanged Polypropylene Technique: A prospective interventional study | <b>Srinivas Joshi, MD, FASRS</b>         |                 |                 |
| Sutureless Flanged Versus Gore-Tex for Secondary IOL implantation: A Comparative Analysis of Surgical Philosophy, Biomechanics, and Clinical Outcomes                | <b>Matias Iglicki, MD</b>                |                 |                 |
| Lens Tilt and Dislocation After Modified Yamane Fixation: Association With Prophylactic Laser to the Optic-Haptic Junction                                           | <b>Harris Sultan, MS, MD</b>             |                 |                 |
| Platform Matters? - Comparative Effectiveness of Five Vitrectomy Systems in 1,082 Primary Vitreoretinal Surgeries                                                    | <b>Obuli Nandhakumar, MD, MRCS, AMPH</b> |                 |                 |
| Discussion                                                                                                                                                           |                                          |                 |                 |
| Break                                                                                                                                                                |                                          | <b>9:43 AM</b>  | <b>10:23 AM</b> |
| <b>AMD - Neovascular Symposium 1. <i>Rethinking nAMD Care: Home OCT, Treatment Burden, and Real-World Barriers</i></b>                                               |                                          | <b>10:23 AM</b> | <b>10:47 AM</b> |
| Longitudinal Performance of a Trend Analysis Algorithm for Home OCT Monitoring in Neovascular Age-related Macular Degeneration (NVAMD)                               | <b>Anat Loewenstein, MD</b>              | 10:23 AM        | 10:26 AM        |
| Macular Ganglion Cell Layer Stability After Repeated Anti-VEGF Therapy in Eyes With and Without Primary Open-Angle Glaucoma                                          | <b>Marco Rovati</b>                      | 10:26 AM        | 10:29 AM        |
| Economic Evaluation of Home OCT: Determinants of Cost-Sparing Potential, Patient Selection, and Clinical Burden                                                      | <b>Sean Berkowitz, MD, MBA</b>           | 10:29 AM        | 10:32 AM        |
| Impact of Treatment Delays Due to Prior Authorization on Short-term Visual Acuity in Neovascular Age-Related Macular Degeneration                                    | <b>Mingyi Huang, MD</b>                  | 10:32 AM        | 10:35 AM        |
| Discussion                                                                                                                                                           |                                          | 10:35 AM        | 10:47 AM        |
| Transition                                                                                                                                                           |                                          | 10:47 AM        | 10:49 AM        |

|                                                                                                                                                              |                                                        |                 |                 |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|-----------------|-----------------|
| <b>Imaging - Digital - Angiography Symposium. <i>Innovations in Retinal Angiography and Functional Imaging</i></b>                                           |                                                        | <b>10:49 AM</b> | <b>11:08 AM</b> |
| Optoretinography (ORG) for Macular Dysfunction                                                                                                               | <b>Kareem Moussa, MD</b>                               | 10:49 AM        | 10:52 AM        |
| Diagnostic accuracy and sensitivity of ultra-widefield steering-based imaging to detect peripheral retinal breaks                                            | <b>Kevin Blinder, MD, FASRS</b>                        | 10:52 AM        | 10:55 AM        |
| Synergistic Visions - OCT Angiography and Dynamic Adaptive Optics Angiography for Clinical Assessment of Retinal Microvasculopathy                           | <b>Richard Rosen, MD, DSc(Hon), FACS, FASRS, FARVO</b> | 10:55 AM        | 10:58 AM        |
| Discussion                                                                                                                                                   |                                                        | 10:58 AM        | 11:08 AM        |
| <i>Transition</i>                                                                                                                                            |                                                        | 11:08 AM        | 11:10 AM        |
| <b>Complications of Anterior Segment Surgery Panel. <i>When Things Go Wrong: Complications and Decision-Making in Secondary IOL Surgery</i></b>              |                                                        | <b>11:10 AM</b> | <b>11:35 AM</b> |
| Comparative Outcomes of Secondary Intraocular Lens Fixation Techniques: Retrospective Analysis of 935 case                                                   | <b>Bryon McKay, MD, PhD, FRCSC, DRCPSC - Retina</b>    |                 |                 |
| Is 20/20 Vision Good Enough? Outcomes of Complete Pars Plana Vitrectomy During IOL Exchange for Lens Opacification in Patients with Preserved Visual Acuity  | <b>Ofri Vorobichik Berar, MD, MHA</b>                  |                 |                 |
| Scleral-Suture Secondary Intraocular Lens Implantation Using a Modified Scleral Mesh (Hash-Tag) Technique: Case Series                                       | <b>Carmen Negrin-Martin, MD</b>                        |                 |                 |
| Structural and Functional Outcomes and Recovery Spectrum in Intracameral Cefuroxime Ocular Toxic Syndrome (ICOTS) in Eyes with Disrupted Intraocular Barrier | <b>Andrea Cusumano, MD</b>                             |                 |                 |
| Discussion                                                                                                                                                   |                                                        |                 |                 |
| <i>Transition</i>                                                                                                                                            |                                                        | <b>11:35 AM</b> | <b>11:37 AM</b> |
| <b>Awards Ceremony</b>                                                                                                                                       |                                                        | <b>11:37 AM</b> | <b>12:14 PM</b> |
| Pyron Award Introduction                                                                                                                                     | <b>Geoffrey G. Emerson, MD, PhD, FASRS</b>             | 11:37 AM        | 11:39 AM        |
| Pyron Award: Title TBD                                                                                                                                       | <b>Glenn Jaffe, MD</b>                                 | 11:39 AM        | 11:44 AM        |
| Founders Award Introduction                                                                                                                                  | <b>Audina Berrocal, MD, FASRS</b>                      | 11:44 AM        | 11:46 AM        |
| Founders Award: From Illumination to Visualization: A Laser Light Source and an Illuminated Vitreous Cutter                                                  | <b>Carl Awh, MD, FASRS</b>                             | 11:46 AM        | 11:51 AM        |
| Young Investigator Award Introduction                                                                                                                        | <b>J. Michael Jumper, MD, FASRS</b>                    | 11:51 AM        | 11:53 AM        |
| Young Investigator Award: The Retina Mosaic                                                                                                                  | <b>Yoshihiro Yonekawa, MD, FASRS</b>                   | 11:53 AM        | 11:58 AM        |

|                                                                                                                                                                 |                                                                                   |                 |                |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------|----------------|
| Packo Award Presentation to Joel Pearlman, MD, PhD                                                                                                              | <b>Geoffrey G. Emerson, MD, PhD, FASRS</b>                                        | 11:58 AM        | 12:00 PM       |
| Crystle Apple Award Presentation to Herbert Culver Boldt, MD                                                                                                    | <b>ECS co-Chairs</b>                                                              | 12:00 PM        | 12:02 PM       |
| WinR Champion Award                                                                                                                                             |                                                                                   | 12:02 PM        | 12:04 PM       |
| Tribute Giving                                                                                                                                                  | <b>J. Michael Jumper, MD, FASRS</b>                                               | 12:04 PM        | 12:06 PM       |
| 2026 M. Gilbert Grand ASRS Vitreoretinal Fellowship Award                                                                                                       |                                                                                   | 12:06 PM        | 12:08 PM       |
| Retina Image Bank Image of the Year                                                                                                                             | <b>Manish Nagpal, MD, MD, FRCS (UK), FASRS and Suber S. Huang, MD, MBA, FASRS</b> | 12:08 PM        | 12:09 PM       |
| Retina Atlas Chapter of the Year                                                                                                                                | <b>Retina Atlas Editors</b>                                                       | 12:09 PM        | 12:10 PM       |
| Retina Hall of Fame Award                                                                                                                                       |                                                                                   | 12:10 PM        | 12:12 PM       |
| Transition                                                                                                                                                      |                                                                                   | 12:12 PM        | 12:14 PM       |
| General Lunch + ECS Lunch                                                                                                                                       |                                                                                   | <b>12:14 PM</b> | <b>1:29 PM</b> |
| <b>Business Meeting</b>                                                                                                                                         |                                                                                   | <b>1:29 PM</b>  | <b>1:44 PM</b> |
| <i>Transition</i>                                                                                                                                               |                                                                                   | 1:44 PM         | 1:46 PM        |
| <b>AMD - Non-neovascular Symposium 1. Beyond Atrophy: Restoring Vision and Redefining Care in Geographic Atrophy</b>                                            |                                                                                   | <b>1:46 PM</b>  | <b>2:10 PM</b> |
| Vision Improvement with Sonporetigene Isteparvovec<br>Optogenetic Therapy in Macular Degeneration: First Direct-to-Phase 2 Randomized, Controlled Trial         | <b>Jordi Mones, MD PhD</b>                                                        | 1:46 PM         | 1:49 PM        |
| From Optical Modelling to First-in-Human Add-On<br>Implantation of the SING IMT™: Translational Feasibility of Dual-Lens Intraocular Systems for Late-Stage AMD | <b>Stanislao Rizzo, MD</b>                                                        | 1:49 PM         | 1:52 PM        |
| Liquid Biopsy Proteomics: Deciphering the Molecular<br>Mechanisms Behind Increased Neovascular AMD Risk After<br>Anti-complement Therapy in Geographic Atrophy  | <b>Tsai-Chu Yeh, MD, MTM</b>                                                      | 1:52 PM         | 1:55 PM        |
| Artificial Intelligence in GA: Learnings from the Pegcetacoplan<br>Clinical Program                                                                             | <b>Paul Hahn, MD, PhD, FASRS</b>                                                  | 1:55 PM         | 1:58 PM        |
| Discussion                                                                                                                                                      |                                                                                   | 1:58 PM         | 2:10 PM        |
| <i>Transition</i>                                                                                                                                               |                                                                                   | 2:10 PM         | 2:12 PM        |
| <b>Diabetic Retinopathy Panel 1. Advancing Durability in Diabetic Retinopathy: New Therapies and Long-Term Data</b>                                             |                                                                                   | <b>2:12 PM</b>  | <b>2:42 PM</b> |
| Long-Term Effectiveness and Safety of Faricimab in Eyes With<br>DME: 2-Year Results From the UK FARWIDE Study                                                   | <b>Sobha Sivaprasad, FRCOphth</b>                                                 |                 |                |

|                                                                                                                                                             |                                           |                |                |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|----------------|----------------|
| Intravitreal Tarcocimab Tedromer for Diabetic Retinopathy: First-time, Primary Endpoint Results from the Phase 3 GLOW2 Trial                                | <b>Charles Wykoff, MD, PhD, FASRS</b>     |                |                |
| Pagoda Trial Results Through Year 4: Port Delivery Platform With Ranibizumab for the Treatment of Diabetic Macular Edema                                    | <b>Luke Lindsell, OD, MD</b>              |                |                |
| Results of a Randomized, Proof-of-Concept Clinical Trial Comparing OLN324 with Faricimab in Patients with Diabetic Macular Edema                            | <b>Veeral Sheth, MD, MBA, FASRS, FACS</b> |                |                |
| Intravitreal Tarcocimab Tedromer for Diabetic Retinopathy: First-time Cross-trial Evaluation of the GLOW and GLOW2 Phase 3 Trials                           | <b>David Brown, MD</b>                    |                |                |
| Discussion                                                                                                                                                  |                                           |                |                |
| Break                                                                                                                                                       |                                           | <b>2:42 PM</b> | <b>3:22 PM</b> |
| <b>Real-World Symposium 2. Managing Macular Edema in the Real World: What the Data Shows</b>                                                                |                                           | <b>3:22 PM</b> | <b>3:46 PM</b> |
| Two-Year Real-World Outcomes of Faricimab for Diabetic Macular Edema: Updated Results from the US FARETINA-DME Expanded 2 year cohort in the IRIS® Registry | <b>Murtaza Adam, MD</b>                   | 3:22 PM        | 3:25 PM        |
| Real-World Use of Aflibercept 8 mg in Eyes with Diabetic Macular Edema (DME): Analysis of the IRIS® Registry (ILLUMIN-8 6-mo)                               | <b>Michael Klufas, MD</b>                 | 3:25 PM        | 3:28 PM        |
| Durability and safety of suprachoroidal triamcinolone acetonide in eyes with chronic cystoid macular edema in real-world clinical practice                  | <b>Sunir Garg, MD, FACS, FASRS</b>        | 3:28 PM        | 3:31 PM        |
| Real-World Clinical Outcomes in Patients With Retinal Vein Occlusion With Macular Edema Treated With Faricimab in the Academy IRIS® Registry                | <b>Rishi Singh, MD</b>                    | 3:31 PM        | 3:34 PM        |
| Discussion                                                                                                                                                  |                                           | 3:34 PM        | 3:46 PM        |
| <i>Transition</i>                                                                                                                                           |                                           | 3:46 PM        | 3:48 PM        |
| <b>Macular Holes &amp; Macular Pucker Panel 1. Beyond the ILM Flap: Advanced Techniques for Complex Macular Holes</b>                                       |                                           | <b>3:48 PM</b> | <b>4:13 PM</b> |
| Impact of Phacoemulsification on Vitreomacular Traction Release and Complications                                                                           | <b>Ananth Sastry, MD</b>                  |                |                |

|                                                                                                                                                                             |                                     |                |                |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|----------------|----------------|
| Beyond the Inverted Flap: Clinical utility of a non-inverted ILM free flap and SPOT technique for primary and refractory Macular Holes                                      | <b>Peiquan Zhao, MD</b>             |                |                |
| Predictors of Anatomic and Functional Success with Amniotic Membrane Grafting for Complex Macular Holes                                                                     | <b>Scott Walter, MD, MSc, FASRS</b> |                |                |
| Distal ILM Flap for Extra-large, XX-large, and Giant Macular Holes                                                                                                          | <b>Homayoun Tabandeh, MD, FASRS</b> |                |                |
| Discussion                                                                                                                                                                  |                                     |                |                |
| <i>Transition</i>                                                                                                                                                           |                                     | 4:13 PM        | 4:15 PM        |
| <b>Technology: Updates in Artificial Intelligence (AI), Augmented Reality, and Robotics. AI in Retina: From Prediction to Clinical and Surgical Decision-Making</b>         |                                     | <b>4:15 PM</b> | <b>4:39 PM</b> |
| Prospective Evaluation of AI-Assisted Screening for Clinical Trials in a Real World Setting                                                                                 | <b>Louis Cai, MD</b>                | 4:15 PM        | 4:18 PM        |
| Predicting Anti-VEGF Treatment Response in Diabetic Macular Edema Using Automated OCT Biomarkers                                                                            | <b>Peter Clark, MD</b>              | 4:18 PM        | 4:21 PM        |
| OCT-F: An AI-Enabled Tool to Determine Retinal Function from OCT                                                                                                            | <b>Srinivas Sadda, MD</b>           | 4:21 PM        | 4:24 PM        |
| The Digital Surgical Cockpit: Transitioning from Qualitative Visualization to Quantitative Decision Support in Subretinal Gene Therapy                                      | <b>Michael Singer, MD</b>           | 4:24 PM        | 4:27 PM        |
| Discussion                                                                                                                                                                  |                                     | 4:27 PM        | 4:39 PM        |
| <i>Transition</i>                                                                                                                                                           |                                     | 4:39 PM        | 4:41 PM        |
| <b>Macular Holes &amp; Macular Pucker Symposium. Beyond the ILM Flap: Advanced Techniques for Complex Macular Holes</b>                                                     |                                     | <b>4:41 PM</b> | <b>5:05 PM</b> |
| Redefining Anatomic Success After Vitrectomy for Lamellar Macular Hole (LMH): Clinical Impact of Persistent or Recurrent LMH and Progression to Full-Thickness Macular Hole | <b>Masaki Fukushima, MD</b>         | 4:41 PM        | 4:44 PM        |
| Spontaneous Progression from Lamellar Macular Hole to Full-Thickness Macular Hole: Timing, Characteristics, and Surgical Outcomes                                           | <b>Kotaro Tsuboi, MD</b>            | 4:44 PM        | 4:47 PM        |

|                                                                                                                                                                          |                                                        |                |                |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|----------------|----------------|
| Postoperative stages of macular hole recovery through transfluid optical coherence tomography: a comparison between minimal gas vitrectomy and fluid-gas exchange        | <b>Yodpong Chantarasorn, MD</b>                        | 4:47 PM        | 4:50 PM        |
| Early Epiretinal Membrane Surgery Is Associated With Improved Visual Outcomes After Macula-On Retinal Detachment: A Large Database Study                                 | <b>Paul de Bustros, MD, MS</b>                         | 4:50 PM        | 4:53 PM        |
| Discussion                                                                                                                                                               |                                                        | 4:53 PM        | 5:05 PM        |
| Transition                                                                                                                                                               |                                                        | 5:05 PM        | 5:10 PM        |
| <b>Scientific Poster Q&amp;A and Exhibit Hall Reception</b>                                                                                                              |                                                        | <b>5:10 PM</b> | <b>6:10 PM</b> |
| <b>Friday, July 17</b>                                                                                                                                                   |                                                        |                |                |
| <b>Experience Center (Fellows &amp; Residents)</b>                                                                                                                       |                                                        | <b>6:30 AM</b> | <b>7:30 AM</b> |
| <b>Continental Breakfast</b>                                                                                                                                             |                                                        | <b>7:15 AM</b> | <b>8:15 AM</b> |
| <b>AMD - Neovascular Symposium 2. <i>Innovations in nAMD: New Targets, New Therapies, Early Results</i></b>                                                              |                                                        | <b>8:00 AM</b> | <b>8:19 AM</b> |
| First-in-Human Evaluation of TH103, a Novel Dual-Targeting VEGF/HSPG Biologic: Phase 1 Single Ascending Dose Study in Treatment-Naïve Neovascular AMD                    | <b>Joel Pearlman, MD, PhD</b>                          | 8:00 AM        | 8:03 AM        |
| Efficacy and Safety of a Novel Topical Peptide (CG-P5) for the Treatment of Neovascular Age-Related Macular Degeneration: Phase 1 Results                                | <b>David Almeida, MD, MBA, PhD, DABO, FRCSC, FASRS</b> | 8:03 AM        | 8:06 AM        |
| Randomized, Controlled, Double-Masked Study to Evaluate the Antimicrobial Efficacy of IRX-101: STERILE Trial Results                                                     | <b>STEPHEN SMITH, MD</b>                               | 8:06 AM        | 8:09 AM        |
| Discussion                                                                                                                                                               |                                                        | 8:09 AM        | 8:19 AM        |
| Transition                                                                                                                                                               |                                                        | 8:19 AM        | 8:21 AM        |
| <b>AMD - Non-neovascular Symposium 2. <i>Emerging Therapies in Geographic Atrophy: Gene Therapy, RNA, and Novel Pathways</i></b>                                         |                                                        | <b>8:21 AM</b> | <b>8:45 AM</b> |
| Subretinal Novel Modifier Gene Therapy (OCU410) for Geographic Atrophy: First-Time 1 year Results from the Phase 2 ArMaDa Trial.                                         | <b>Arshad Khanani, MD, MA, FASRS</b>                   | 8:21 AM        | 8:24 AM        |
| Phase 1/2 Evaluation of OCU410 Novel Modifier Gene Therapy for Geographic Atrophy and Stargardt Disease: Quantitative FAF and SD-OCT Lesion Analysis and Safety Outcomes | <b>Jay Chhablani</b>                                   | 8:24 AM        | 8:27 AM        |

|                                                                                                                                                      |                                  |                |                |
|------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|----------------|----------------|
| Phase 1 results of APL-3007: A novel systemic C3 siRNA for geographic atrophy secondary to AMD                                                       | <b>Mathew MacCumber, MD, PhD</b> | 8:27 AM        | 8:30 AM        |
| A Phase 2 Clinical Trial of the Inflammasome Inhibitor K8 in Bilateral Geographic Atrophy (GA)                                                       | <b>Jayakrishna Ambati, MD</b>    | 8:30 AM        | 8:33 AM        |
| Discussion                                                                                                                                           |                                  | 8:33 AM        | 8:45 AM        |
| <i>Transition</i>                                                                                                                                    |                                  | 8:45 AM        | 8:47 AM        |
| <b>Closing the Gap: Translating Emerging Therapies into Real-World Outcomes in GA</b>                                                                |                                  | <b>8:47 AM</b> | <b>9:11 AM</b> |
| Outcomes in Geographic Atrophy: Real-World Evidence from EHR Data and AI-Based Imaging in Patients Treated with Pegcetacoplan                        | <b>Nimesh Patel, MD, FASRS</b>   | 8:47 AM        | 8:50 AM        |
| Earlier treatment yields better outcomes: 5 years of pegcetacoplan treatment for geographic atrophy secondary to AMD                                 | <b>Esther Kim, MD</b>            | 8:50 AM        | 8:53 AM        |
| Real-World Utilization, Retention, Safety, and Outcomes of Pegcetacoplan Therapy for Geographic Atrophy in Patients with Follow-up of Two Years      | <b>Alexander Miller, MD</b>      | 8:53 AM        | 8:56 AM        |
| Assessment of Geographic Atrophy Progression Following Pegcetacoplan in the Real-world With and Without Neovascular Age-related Macular Degeneration | <b>Hasenin Al-khersan, MD</b>    | 8:56 AM        | 8:59 AM        |
| Discussion                                                                                                                                           |                                  | 8:59 AM        | 9:11 AM        |
| <i>Transition</i>                                                                                                                                    |                                  | 9:11 AM        | 9:13 AM        |
| <b>Inflammatory and Infectious Diseases Symposium. Uveitis and Ocular Infection: Evolving Diagnosis and Treatment Strategies</b>                     |                                  | <b>9:13 AM</b> | <b>9:54 AM</b> |
| Safety of Anti-VEGF Injections in Patients with Uveitis                                                                                              | <b>Mitchell Allphin, MD</b>      | 9:13 AM        | 9:16 AM        |
| Long term visual, anatomical and treatment outcomes in eyes                                                                                          | <b>Sruthi Arepalli, MD</b>       | 9:16 AM        | 9:19 AM        |
| Ocular Syphilis and Regional Variation in Lumbar Puncture                                                                                            | <b>Mark Breazzano, MD, FACS</b>  | 9:19 AM        | 9:22 AM        |
| Discussion                                                                                                                                           |                                  | 9:22 AM        | 9:32 AM        |
| Disease-Modifying Strategies in Autoimmune Retinopathy                                                                                               | <b>Majda Hadziahmetovic, MD</b>  | 9:32 AM        | 9:35 AM        |
| Long-Term Outcomes of Pediatric Vogt–Koyanagi–Harada Disease                                                                                         | <b>Sulaiman Al Sulaiman, MD</b>  | 9:35 AM        | 9:38 AM        |
| Postoperative Sarcoidosis kiliense endophthalmitis                                                                                                   | <b>Makoto Inoue, MD, FASRS</b>   | 9:38 AM        | 9:41 AM        |
| Multimodal Suprachoroidal Space Imaging Reveals Opening                                                                                              | <b>Glenn Yiu, MD, PhD</b>        | 9:41 AM        | 9:44 AM        |

|                                                                                                                                               |                                                   |          |          |
|-----------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|----------|----------|
| Discussion                                                                                                                                    |                                                   | 9:44 AM  | 9:54 AM  |
| <i>Transition</i>                                                                                                                             |                                                   | 9:54 AM  | 9:56 AM  |
| <b>Trauma &amp; PVR Symposium. <i>Decision-Making, Surgical Strategies, and Case-Based Insights</i></b>                                       |                                                   |          |          |
| Objective Ocular Trauma Score (oOTS): A Visual Acuity-Independent Model With Discrimination Comparable to OTS                                 | <b>Shulamit Schwartz, MD</b>                      | 9:56 AM  | 10:05 AM |
| tPA-Assistant Trauma Surgery                                                                                                                  | <b>Adiel Barak, MD</b>                            | 9:59 AM  | 10:02 AM |
| Outcomes of Complex PVR Retinal Detachment Repair with and without Intravitreal Methotrexate at a Single Tertiary Care Center                 | <b>John Miller, MD</b>                            | 10:02 AM | 10:05 AM |
| <b>Break</b>                                                                                                                                  |                                                   |          |          |
| <b>Hereditary Retinal Disease &amp; Genetics Symposium. <i>Emerging Therapeutic and Diagnostic Advances in Inherited Retinal Diseases</i></b> |                                                   |          |          |
| Intravitreal RNA Therapy for PRPF31-Associated Retinitis Pigmentosa: Results from a Phase 1b Multiple Ascending Dose Study of VP-001          | <b>Robert Bhisitkul, MD, PhD</b>                  | 10:45 AM | 11:06 AM |
| Subretinal laru-zova Gene Therapy for XLRP: Preliminary Safety, Efficacy and Surgical Technique in the Phase 2 Multicenter DAWN Trial         | <b>Robert Sisk, MD, FACS, FASRS</b>               | 10:48 AM | 10:51 AM |
| Enhancing Molecular Diagnostic Accuracy in Inherited Retinal Dystrophies Through a Personalized Re-Evaluation Strategy                        | <b>João Pedro Marques, MD, MSc, PhD, FEBOphth</b> | 10:51 AM | 10:54 AM |
| Discussion                                                                                                                                    |                                                   | 10:54 AM | 11:06 AM |
| <i>Transition</i>                                                                                                                             |                                                   | 11:06 AM | 11:08 AM |
| <b>Diabetic Retinopathy Symposium. <i>Innovations in Diabetic Retinopathy: New Therapies, Delivery Systems, and Disease Biology</i></b>       |                                                   |          |          |
| Oral Tonabersat Connexin-43 Modulator for Diabetic Macular Edema with Good Vision (DRCR Protocol AN)                                          | <b>Andrew Barkmeier, MD</b>                       | 11:08 AM | 11:11 AM |
| Sustained-release PER-001 Intravitreal Implant: Structural and Visual Function Improvements in Patients with Diabetic Retinopathy             | <b>Saradha Chexal, MD</b>                         | 11:11 AM | 11:14 AM |

|                                                                                                                                                                           |                                                          |                 |                 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|-----------------|-----------------|
| Suprachoroidal Delivery of Investigational Gene Therapy Surabgene Lomparvovec (Sura-vec, ABBV-RGX-314): Results in NPDR at 2.5 Years                                      | <b>David Boyer, MD</b>                                   | 11:14 AM        | 11:17 AM        |
| Adrenaline vs Tranexamic Acid for Intraoperative Hemostasis in PDR Vitrectomy: A Randomized Trial                                                                         | <b>SHISHIR VERGHESE, MS, FVRS, FAICO (Retina)</b>        | 11:17 AM        | 11:20 AM        |
| <b>Fellows Forum Award Winner:</b> Multiomic analysis of human diabetic retinal disease reveals severity and region-specific impairment of the retinal neurovascular unit | <b>Rachana Haliyur, MD, PhD</b>                          | 11:20 AM        | 11:23 AM        |
| Discussion                                                                                                                                                                |                                                          | 11:23 AM        | 11:38 AM        |
| <i>Transition</i>                                                                                                                                                         |                                                          | 11:38 AM        | 11:40 AM        |
| <b>Retinal Vascular Disease Symposium. <i>Retinal Vascular Occlusions: Treatment Strategies, Outcomes, and Emerging Approaches</i></b>                                    |                                                          | <b>11:40 AM</b> | <b>12:18 PM</b> |
| Tiespectus (MK-8748) for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion: Phase 1/2a Rioja Clinical Study                                       | <b>Baruch Kuppermann, MD, PhD, FASRS</b>                 | 11:40 AM        | 11:43 AM        |
| Retinal Vein Occlusion with Good Baseline Visual Acuity: Immediate Treatment vs. Initial Observation                                                                      | <b>Ajay Kuriyan, MD, MS</b>                              | 11:43 AM        | 11:46 AM        |
| Impact of Baseline Central Retinal Thickness on Visual and Anatomic Outcomes in Macular Edema Following RVO: A QUASAR Post hoc analysis through Wk 36                     | <b>Ehsan Rahimy, MD</b>                                  | 11:46 AM        | 11:49 AM        |
| Discussion                                                                                                                                                                |                                                          | 11:49 AM        | 11:59 AM        |
| Outcomes after low-IOP vitrectomy combined with arteriovenous sheathotomy, ILM peeling with a brief induced IOP fluctuation in Central Retinal Artery Occlusion           | <b>Subhendu Boral, MBBS, MD(AIIMS), DNB, FASRS (USA)</b> | 11:59 AM        | 12:02 PM        |
| Clinical Outcomes of Switching Back to Intravitreal Bevacizumab Therapy                                                                                                   | <b>Mary Gao, DO</b>                                      | 12:02 PM        | 12:05 PM        |
| Detecting retrobulbar emboli with orbital ultrasonography to predict neovascular glaucoma in central retinal artery occlusion                                             | <b>Erik Massenzio, MD</b>                                | 12:05 PM        | 12:08 PM        |
| Discussion                                                                                                                                                                |                                                          | 12:08 PM        | 12:18 PM        |
| General Lunch + Fellowship Directors Section Lunch                                                                                                                        |                                                          | <b>12:18 PM</b> | <b>1:33 PM</b>  |
| <b>Socioeconomics/Practice Management Panel. <i>Health Systems and Equity in Retina Care</i></b>                                                                          |                                                          | <b>1:33 PM</b>  | <b>2:03 PM</b>  |

|                                                                                                                                    |                                   |                |                |
|------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|----------------|----------------|
| Impact of Social Deprivation and Vulnerability on Patients With DME: Results From ELEVATUM and YOSEMITE/RHINE                      | <b>Mohsin Ali, MD</b>             |                |                |
| Baseline Biomarker Levels in Underrepresented Patients With DME: A Post Hoc Exploratory Analysis of ELEVATUM                       | <b>Adrienne Scott, MD, FASRS</b>  |                |                |
| Real-World Impact of Step Therapy Requirements on Access to Faricimab and Treatment Burden                                         | <b>Sabin Dang, MD</b>             |                |                |
| Impact of Loss of Good Days Copay Assistance Program on Clinical and Anatomical Outcomes of Retinal Disease                        | <b>Danny Mammo, MD</b>            |                |                |
| Impact of Good Days Underfunding on Treatment Patterns and Outcomes in Patients with Neovascular Age-Related Macular Degeneration  | <b>Abdullah Abou-Samra, MD</b>    |                |                |
| Discussion                                                                                                                         |                                   |                |                |
| <i>Transition</i>                                                                                                                  |                                   | 2:03 PM        | 2:05 PM        |
| <b>Policy Panel</b>                                                                                                                |                                   | <b>2:05 PM</b> | <b>2:35 PM</b> |
| <i>Transition</i>                                                                                                                  |                                   | 2:35 PM        | 2:37 PM        |
| <b>Socioeconomics/Practice Management Symposium. Health Disparities in Retina Care: Policy, Geography, and Population Outcomes</b> |                                   | <b>2:37 PM</b> | <b>3:15 PM</b> |
| Access to Intravitreal Anti-VEGF Drugs in Persons with Medicare Advantage Compared with Medicare Fee for Service                   | <b>Ravi Parikh, MD MPH</b>        | 2:37 PM        | 2:40 PM        |
| Comparison of Medicaid vs Medicare Reimbursements Rates for Vitreoretinal Surgeries in the United States                           | <b>Ella Leung, MD</b>             | 2:40 PM        | 2:43 PM        |
| Diabetic Retinopathy Outcomes Among Unhoused Individuals: A Big Data Analysis                                                      | <b>Judy Kim, MD, FARVO, FASRS</b> | 2:43 PM        | 2:46 PM        |
| Discussion                                                                                                                         |                                   | 2:46 PM        | 2:56 PM        |
| Impact of Geographic and Socioeconomic Factors on Endophthalmitis Presentation and Outcomes                                        | <b>Bivek Wagle, MD</b>            | 2:56 PM        | 2:59 PM        |
| Access to Pediatric Retina Care by Geographic Distribution and US Population Demographic Characteristics in 2025                   | <b>Hong-Uyen Hua, MD</b>          | 2:59 PM        | 3:02 PM        |
| The effects of Social and Demographic Factors on Severity of Inherited Retinal Diseases at the Time of Genetic Testing             | <b>Milam Brantley, MD, PhD</b>    | 3:02 PM        | 3:05 PM        |
| Discussion                                                                                                                         |                                   | 3:05 PM        | 3:15 PM        |
| <i>Transition</i>                                                                                                                  |                                   | 3:15 PM        | 3:17 PM        |

|                                                                                                                                                     |                                                                     |                |                |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|----------------|----------------|
| Panel Discussion: Impact of Vitrectomy on Light Adjustable Lenses Before Final Laser Lock-in in Post-Cataract Surgery Patients                      | <b>Osama Sabbagh, MD</b>                                            | 3:17 PM        | 3:27 PM        |
| Break                                                                                                                                               |                                                                     | <b>3:27 PM</b> | <b>4:07 PM</b> |
| <b>Pediatric Retina - The Michael Trese Symposium in Pediatric Retina</b>                                                                           |                                                                     | <b>4:07 PM</b> | <b>4:50 PM</b> |
| ICROP3 Zone I Definition Varies with Post Menstrual Age and is Not Consistent with Type 1 ETROP Treatment Zone I Definition                         | <b>Darius Moshfeghi, MD, FASRS</b>                                  | 4:07 PM        | 4:10 PM        |
| Tele-screening is associated with reduced treatment rates in a large cohort of infants at risk for retinopathy of prematurity.                      | <b>Eugenia Greig, MD</b>                                            | 4:10 PM        | 4:13 PM        |
| Retinopathy of Prematurity in Infants Born at 22 Weeks of Gestational Age                                                                           | <b>Sahal Saleh, MD</b>                                              | 4:13 PM        | 4:16 PM        |
| Discussion                                                                                                                                          |                                                                     | 4:16 PM        | 4:26 PM        |
| Atypical regression patterns of Retinopathy of Prematurity, post combined therapy with intravitreal Anti-VEGF and laser photocoagulation.           | <b>Bibhuti Kashyap, MD, FACS, DNB, FRCSEd, FRCS (GLASGOW), FICO</b> | 4:26 PM        | 4:29 PM        |
| Outcomes of a combined surgical approach for stage 5 ROP: A prospective interventional case series                                                  | <b>Sameera Nayak, MBBS, MS, FRCS</b>                                | 4:29 PM        | 4:32 PM        |
| Choroidal Vascularity Index and Choroidal Area in Stage 3+ ROP Eyes Treated With Anti-VEGF With or Without Laser                                    | <b>Swati Agarwal-Sinha, MD, FASRS</b>                               | 4:32 PM        | 4:35 PM        |
| Comparative Axial Elongation Rates in High Myopia With and Without Retinopathy of Prematurity                                                       | <b>Melissa Yuan, MD</b>                                             | 4:35 PM        | 4:38 PM        |
| Discussion                                                                                                                                          |                                                                     | 4:38 PM        | 4:50 PM        |
| <i>Transition</i>                                                                                                                                   |                                                                     | 4:50 PM        | 4:52 PM        |
| <b>MacTel Panel. Macular Telangiectasia Type 2: Imaging, Emerging Therapies, and Clinical Outcomes</b>                                              |                                                                     | <b>4:52 PM</b> | <b>5:22 PM</b> |
| Ellipsoid Zone Area Loss Is an Independent Predictor of Reduced Fixation Stability in Macular Telangiectasia Type 2                                 | <b>Eleonora Lad, MD, PhD</b>                                        |                |                |
| Longitudinal Multimodal Imaging and Clinical Outcomes in Individuals Who Received Revakinagene Taroretcel-Iwey Encapsulated Cell Therapy for MacTel | <b>Lydia Sauer, MD</b>                                              |                |                |

|                                                                                                                                                                                  |  |                                       |                |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|---------------------------------------|----------------|
| Reading Speed Outcomes in Macular Telangiectasia Type 2:<br>Sham-Control Data From the Phase 3 Revakinagene Taroretcel- <b>Dean Elliott, MD</b><br>Iwey (NT-501) Trials          |  |                                       |                |
| Surgical-Related Adverse Events With Revakinagene<br>Taroretcel-Iwey in Macular Telangiectasia Type 2: A Root<br>Cause Analysis                                                  |  | <b>W. Clark, MD, FASRS</b>            |                |
| Misdiagnosis of Macular Telangiectasia Type 2 in the Era of<br>Neuroprotective Therapy<br>Discussion                                                                             |  | <b>Robin Vora, MD</b>                 |                |
| Transition                                                                                                                                                                       |  | 5:22 PM                               | 5:30 PM        |
| <b>WinR Case Conference</b>                                                                                                                                                      |  | <b>5:30 PM</b>                        | <b>7:15 PM</b> |
| <b>FIT &amp; Resident Reception</b>                                                                                                                                              |  | <b>6:00 PM</b>                        | <b>8:00 PM</b> |
| <b>Saturday, July 18</b>                                                                                                                                                         |  |                                       |                |
| <b>Empowerment &amp; Opportunity Mentoring Breakfast</b>                                                                                                                         |  |                                       |                |
| <b>Experience Center (Fellows &amp; Residents)</b>                                                                                                                               |  | <b>6:30 AM</b>                        | <b>7:30 AM</b> |
| <b>Continental Breakfast</b>                                                                                                                                                     |  | <b>7:15 AM</b>                        | <b>8:15 AM</b> |
| <b>Retinal Detachment Panel. <i>Retinal Detachment: PVR<br/>Prevention, Surgical Outcomes, and Risk Factors</i></b>                                                              |  |                                       |                |
| Statin Use and Association with Proliferative<br>Vitreoretinopathy and Reoperation Risk Following Retinal<br>Detachment Surgery                                                  |  | <b>8:00 AM</b>                        | <b>8:20 AM</b> |
| Trends in Centralization of Urgent Versus Elective<br>Vitreoretinal Surgery in the Medicare Fee-For-Service<br>Population: 2017-2023                                             |  | <b>Christina Weng, MD, MBA, FASRS</b> |                |
| Interim Report #2 of the FIXER - Methotrexate Trial<br>(Prevention of Proliferative Vitreoretinopathy<br>with Intravitreal Methotrexate in Primary<br>Retinal Detachment Repair) |  | <b>Stephanie Engelhard, MD</b>        |                |
| Discussion                                                                                                                                                                       |  | <b>Christopher Riemann, MD</b>        |                |
| Transition                                                                                                                                                                       |  | 8:20 AM                               | 8:22 AM        |
| <b>Retinal Detachment Symposium 1. <i>Retinal Detachment: Risk<br/>Stratification, Prophylaxis, and Imaging Insights</i></b>                                                     |  |                                       |                |
|                                                                                                                                                                                  |  | <b>8:22 AM</b>                        | <b>8:46 AM</b> |

|                                                                                                                                                        |                                      |                |                 |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|----------------|-----------------|
| Retinopexy prophylaxis of lattice degeneration in fellow eyes after rhegmatogenous detachment: results from a large national database                  | <b>Ahmed Shakarchi, MD, MPH</b>      | 8:22 AM        | 8:25 AM         |
| Retinopexy Prophylaxis for Lattice Degeneration Without Retinal Breaks: A Large Retrospective Cohort Study                                             | <b>Ahmed Sallam, MD PhD FRCOphth</b> | 8:25 AM        | 8:28 AM         |
| Outer Retinal Corrugations Indicate Retinal Break Status in Rhegmatogenous Retinal Detachment                                                          | <b>Jeffrey Mah, MD</b>               | 8:28 AM        | 8:31 AM         |
| Outer Retinal Corrugation Biomechanics Predict Outer Retinal Folds and Visual Acuity in Rhegmatogenous Retinal Detachment                              | <b>Isabela Martins Melo, MD</b>      | 8:31 AM        | 8:34 AM         |
| Discussion                                                                                                                                             |                                      | 8:34 AM        | 8:46 AM         |
| <i>Transition</i>                                                                                                                                      |                                      | 8:46 AM        | 8:48 AM         |
| <b>Hereditary Retinal Disease &amp; Genetics Panel. <i>Stargardt Disease: Emerging Therapies, Biomarkers, and Clinical Trial Design</i></b>            |                                      | <b>8:48 AM</b> | <b>9:13 AM</b>  |
| Results of the Phase 3 DRAGON Trial of Tinalarebant (LBS-008) for Stargardt Disease (STGD1)                                                            | <b>Paul Bernstein, MD, PhD</b>       |                |                 |
| Oral Gildeuretinol for Slowing Stargardt Disease Progression: Safety and Efficacy Data from the Phase 2 TEASE Study and Follow-up Phase 3 Study Design | <b>Christine Kay, MD</b>             |                |                 |
| Relationship of Three Atrophy Growth Rate Metrics with Lesion Shape Factors in Stargardt Disease: Implications for Clinical Trial Design               | <b>Liangbo Shen, MD</b>              |                |                 |
| Automated Quantification of Decreased FAF in Stargardt Disease Using Starguage: Validation Against Manual Grading Standards                            | <b>Jia-Horung Hung, MD, PhD</b>      |                |                 |
| Discussion                                                                                                                                             |                                      |                |                 |
| <i>Transition</i>                                                                                                                                      |                                      | 9:13 AM        | 9:15 AM         |
| <b>Best of JVRD and Journal Updates</b>                                                                                                                |                                      | <b>9:15 AM</b> | <b>9:30 AM</b>  |
| <i>Transition</i>                                                                                                                                      |                                      | 9:30 AM        | 9:32 AM         |
| Break                                                                                                                                                  |                                      | <b>9:32 AM</b> | <b>10:12 AM</b> |

| <b>Pharmacology Symposium. <i>Balancing Risk and Benefit: Pharmacologic Safety in Retina Care</i></b>                                                   |                                                | <b>10:12 AM</b> | <b>10:36 AM</b> |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|-----------------|-----------------|
| Association of Peri-Event Anti-VEGF with Mortality and Sequelae Following Stroke or Myocardial Infarction                                               | <b>Darius Bordbar, MD</b>                      | 10:12 AM        | 10:15 AM        |
| Safety of Continuing Anti-VEGF Therapy Around the Time of Nonophthalmic Incisional Surgery: A Multisite Matched Cohort Study                            | <b>Odette Houghton, MD</b>                     | 10:15 AM        | 10:18 AM        |
| 'Drop less Vitrectomy' with 'Suprachoroidal Trimoxi' for epiretinal membranes: A Comparative Analysis of Safety and Efficacy with standard of care topi | <b>K. Chalam, MD, PhD, MBA, FRCS(C), FASRS</b> | 10:18 AM        | 10:21 AM        |
| A Pilot Study Evaluating Safety and Patient Comfort of a Compounded Povidone-Iodine and Proparacaine Combination                                        | <b>Ivan Suñer, MD, MBA</b>                     | 10:21 AM        | 10:24 AM        |
| Discussion                                                                                                                                              |                                                | 10:24 AM        | 10:36 AM        |
| <i>Transition</i>                                                                                                                                       |                                                | 10:36 AM        | 10:38 AM        |
| <b>AMD - Non-neovascular Symposium 3. <i>Geographic Atrophy: Functional Outcomes, Treatment Response, and Predictive Biomarkers</i></b>                 |                                                | <b>10:38 AM</b> | <b>10:57 AM</b> |
| Structure–Function Link of the Ellipsoid Zone and Low Luminance Deficit in Geographic Atrophy with Monthly and Every-Other-Month Avacincaptad Pegol     | <b>Rachel Downes, MD</b>                       | 10:38 AM        | 10:41 AM        |
| Pegcetacoplan versus Avacincaptad pegol: Efficacy of Treatment in the Same Eye                                                                          | <b>Josh Wallsh</b>                             | 10:41 AM        | 10:44 AM        |
| Baseline Characteristics Associated With Loss of BCVA $\geq$ 15 ETDRS Letters in Participants With Geographic Atrophy in the Phase 2 ARCHER Study       | <b>Margaret Chang, MD, MS</b>                  | 10:44 AM        | 10:47 AM        |
| Discussion                                                                                                                                              |                                                | 10:47 AM        | 10:57 AM        |
| <i>Transition</i>                                                                                                                                       |                                                | 10:57 AM        | 10:59 AM        |
| <b>Real-World Retina: Outcomes, Complications, and Risk Stratification</b>                                                                              |                                                | <b>10:59 AM</b> | <b>11:30 AM</b> |
| Incidence, prevalence and risk factors for pathologic myopia and associated complications: a multi-center database study                                | <b>Michael Fliotsos, MD</b>                    | 10:59 AM        | 11:02 AM        |
| Incidence and risk factors of retinal tear and detachment after YAG capsulotomy: an IRIS® Registry (Intelligent Research in Sight) analysis             | <b>Jordan Deaner, MD</b>                       | 11:02 AM        | 11:05 AM        |

|                                                                                                                                                                                                                                          |                                                              |                 |                 |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|-----------------|-----------------|
| Ten-Year Real-World Outcomes of Intravitreal Antibiotics Alone, Deferred Vitrectomy, and Immediate Vitrectomy for Acute Post-Cataract Endophthalmitis Discussion                                                                         | <b>Aditya Kelkar, MS, FRCS, FASRS, FRCOphth</b>              | 11:05 AM        | 11:08 AM        |
|                                                                                                                                                                                                                                          |                                                              | 11:08 AM        | 11:18 AM        |
| Endophthalmitis Following Pars Plana Vitrectomy: An IRIS® Registry Study                                                                                                                                                                 | <b>Matthew Starr, MD, FASRS</b>                              | 11:18 AM        | 11:21 AM        |
| Proliferative Vitreoretinopathy in Contemporary Retinal Detachment Surgery: Socioeconomic, Surgical, and Ocular Determinants in the IRIS® Registry Discussion                                                                            | <b>Leo Kim, MD, PhD</b>                                      | 11:21 AM        | 11:24 AM        |
|                                                                                                                                                                                                                                          |                                                              | 11:24 AM        | 11:30 AM        |
| <i>Transition</i>                                                                                                                                                                                                                        |                                                              | 11:30 AM        | 11:32 AM        |
| <b>Macular Holes &amp; Macular Pucker Panel 2. Macular Surgery Complications: Outcomes After Vitrectomy for Hole and Pucker</b>                                                                                                          |                                                              |                 |                 |
| Persistent cystoid macular edema after vitrectomy for epiretinal membrane removal                                                                                                                                                        | <b>Libby Wei, MD</b>                                         | <b>11:32 AM</b> | <b>11:57 AM</b> |
| Epiretinal Membrane Risk After Prophylactic Laser Photocoagulation for Lattice Degeneration                                                                                                                                              | <b>Marta Stevanovic, MD, MSc</b>                             |                 |                 |
| Increased Risk of Retinal Detachment in Combined Phacovitrectomy versus Sequential Surgery for Macular Progression of Macular Atrophy after Vitrectomy for Myopic Traction Maculopathy: Incidence, Risk Factors, and Outcomes Discussion | <b>Charles Zhang, MD</b><br><b>Taku Wakabayashi, MD, PhD</b> |                 |                 |
| General Lunch + WinR Lunch                                                                                                                                                                                                               |                                                              | <b>11:57 AM</b> | <b>1:12 PM</b>  |
| <b>Retinaws</b>                                                                                                                                                                                                                          |                                                              | <b>1:12 PM</b>  | <b>2:12 PM</b>  |
| <i>Transition</i>                                                                                                                                                                                                                        |                                                              | 2:12 PM         | 2:14 PM         |
| <b>Ocular Oncology Symposium. Uveal Melanoma: From Biopsy to Biomarkers to Clinical Decision-Making</b>                                                                                                                                  |                                                              |                 |                 |
| Viscous Fluid Control Assisted Fine-Needle Aspiration Biopsy for Uveal Melanoma: Surgical Technique                                                                                                                                      | <b>Gordon Crabtree, MD</b>                                   | 2:14 PM         | 2:17 PM         |

|                                                                                                                                                                  |                                       |                |                |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|----------------|----------------|
| Gene Expression Profiling for Uveal Melanoma: The first decade and beyond defines best care for our patients                                                     | <b>Timothy Murray, MD, MBA, FASRS</b> | 2:17 PM        | 2:20 PM        |
| Limits of Mutation Profiling as a Predictor of 15-GEP/PRAME Risk in Uveal Melanoma                                                                               | <b>David Reichstein, MD</b>           | 2:20 PM        | 2:23 PM        |
| Clinicopathologic characteristics, gene expression, and metastatic risk of uveal melanomas with no uveal melanoma-associated mutations (no UMAMs)                | <b>Amy Scheffler, MD FACS FASRS</b>   | 2:23 PM        | 2:26 PM        |
| Prophylactic bevacizumab after Plaque Brachytherapy in high-risk posterior uveal melanoma: Impact on development of radiation retinopathy                        | <b>Prithvi Mruthyunjaya, MD, MHS</b>  | 2:26 PM        | 2:29 PM        |
| Discussion                                                                                                                                                       |                                       | 2:29 PM        | 2:44 PM        |
| Break                                                                                                                                                            |                                       | <b>2:44 PM</b> | <b>3:24 PM</b> |
| <b>Best of Business of Retina</b>                                                                                                                                |                                       | 3:24 PM        | 3:39 PM        |
| <i>Transition</i>                                                                                                                                                |                                       | 3:39 PM        | 3:41 PM        |
| <b>Creative Awards</b>                                                                                                                                           |                                       | <b>3:41 PM</b> | <b>4:06 PM</b> |
| <i>Transition</i>                                                                                                                                                |                                       | 4:06 PM        | 4:08 PM        |
| <b>Diabetic Retinopathy Panel 2. <i>Diabetic Retinopathy: Outcomes and Predictors</i></b>                                                                        |                                       | <b>4:08 PM</b> | <b>4:33 PM</b> |
| Impact of Baseline Subretinal Fluid on Treatment Outcomes in DME: Analysis of the Phase 3 YOSEMITE and RHINE Trials                                              | <b>Rolake Alabi, MD PhD</b>           |                |                |
| Baseline Macular Vascular Status Determines Perfusion and Visual Recovery After Panretinal Photocoagulation in Severe Diabetic Retinopathy Without Macular Edema | <b>Eoi Jong Seo, MD, PhD</b>          |                |                |
| Assessment of Intraretinal Cyst Turbidity on Optical Coherence Tomography: Clinical Implications in DME From YOSEMITE/RHINE                                      | <b>Andreas Pollreis, MD</b>           |                |                |
| The Association Between Diabetic Retinopathy Severity and Dementia Risk                                                                                          | <b>Manju Subramanian, MD</b>          |                |                |
| Discussion                                                                                                                                                       |                                       |                |                |
| <i>Transition</i>                                                                                                                                                |                                       | 4:33 PM        | 4:35 PM        |
| <b>Retinal Detachment Symposium 2. <i>Beyond Routine RD: Complex Cases, AI Prediction, and Surgical Decision-Making</i></b>                                      |                                       | <b>4:35 PM</b> | <b>4:59 PM</b> |

|                                                                                                                                                                      |                                             |         |         |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------|---------|
| Predicting the Location of Retinal Tears in Eyes with Rhegmatogenous Retinal Detachment Using Artificial Intelligence                                                | <b>John Thompson, MD</b>                    | 4:35 PM | 4:38 PM |
| Clinical features of retinal detachment (RD) following prophylactic retinopexy in children with Stickler syndrome: implications for optimal treatment and management | <b>Franco Recchia, MD</b>                   | 4:38 PM | 4:41 PM |
| Colobomatous Retinal Detachments: A Single Center Retrospective Analysis                                                                                             | <b>Amer Alsoudi, MD</b>                     | 4:41 PM | 4:44 PM |
| Scleral Buckle Revision in the Vitrectomy Era                                                                                                                        | <b>Irmak Karaca, MD, FEBO, FICO, MRCSEd</b> | 4:44 PM | 4:47 PM |
| Discussion                                                                                                                                                           |                                             | 4:47 PM | 4:59 PM |
| Closing Reception: Marche Bonsecours                                                                                                                                 |                                             | 7:00 PM |         |